Skip to main
NDRA

NDRA Stock Forecast & Price Target

NDRA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ENDRA Life Sciences Inc. is positioned for growth due to its innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which is designed to enhance diagnostic capabilities for liver diseases affecting over one billion people globally. The potential approval from the FDA within the next year serves as a key catalyst that could drive the stock higher, supported by a favorable net present value (NPV) analysis indicating significant upside potential. Additionally, TAEUS technology promises to provide more accurate and cost-effective diagnostics and monitoring of liver diseases compared to existing methods, highlighting an important market opportunity.

Bears say

ENDRA Life Sciences Inc reported a net loss of $1.6 million for the latest period, translating to an earnings per share (EPS) of $(2.10), which was worse than previous estimates of $(1.95). The company continues to face significant challenges, including balance sheet and liquidity risks, a lack of successful clinical trials for its product candidates, and difficulties related to regulatory approvals and commercialization efforts. Various external factors, including competition and changes in healthcare priorities, contribute to an overall negative outlook for the stock amidst these financial hurdles.

NDRA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ENDRA Life Sciences (NDRA) Forecast

Analysts have given NDRA a Strong Buy based on their latest research and market trends.

According to 1 analysts, NDRA has a Strong Buy consensus rating as of Jan 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ENDRA Life Sciences (NDRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.